Rheonix Invited to Present at 'The Future of In-Vitro Diagnostics' Conference hosted by Siemens

Rheonix Invited to Present at 'The Future of In-Vitro Diagnostics' Conference
                              hosted by Siemens

Developer of 'Elegantly Simple' Rheonix CARD® Microfluidic Device Makes
Complex Molecular Diagnostics Simpler, More Accurate, Comprehensive, and Cost

PR Newswire

ITHACA, N.Y., March 24, 2014

ITHACA, N.Y., March 24, 2014 /PRNewswire/ --Rheonix, Inc., a developer of
fully automated molecular testing solutions, announced today that it has been
invited to exhibit at "The Future of In-Vitro Diagnostics." The exclusive
conference, held April 10, 2014 in Menlo Park/Palo Alto, CA, is hosted by
Siemens Venture Capital, the investment arm of Siemens, and Siemens

The fifth annual conference brings together over 100 CEOs and CTOs, investors,
key opinion leaders, and clinicians from the in vitro diagnostic industry
along with Siemens' executive and technical teams. Only companies identified
by Siemens as among "the most attractive in their field" were invited. The
invited companies will present, exhibit, and attendees will be highlighted in
the conference booklet and mentioned at the event.

Rheonix's innovative products fully automate the molecular analysis of a wide
variety of samples, such as tissue, swabs, or blood, for assays ranging from
oncology to infectious disease. Rheonix's core product is a microfluidic
device called the Chemistry and Reagent Device, or Rheonix CARD^®, a simple,
disposable cartridge that accepts a raw sample, applied by a laboratory
technician. The CARD is then interfaced with Rheonix's instrument, the
EncompassMDx™, which controls the CARD's performance of molecular assays from
start to finish without human intervention. The resulting highly multiplexed
assays are able to transform data into clinically relevant diagnostic
information more effectively than conventional approaches. The EncompassMDx
processes multiple CARD's simultaneously, which will allow clinical labs to
increase their productivity while maintaining existing staffing levels.

Rheonix's products simplify the entire molecular diagnostic testing process by
eliminating the need for multiple pieces of equipment, decreasing hands-on
technician time, and producing results quickly, more efficiently, and more
cost-effectively, while eliminating opportunity for human error. Rheonix's
approach addresses a key need of patients, physicians, and laboratories for
access to easy to use devices that are capable of delivering more information
in a cost-effective manner in everyday settings.

"Our invitation to the Siemens healthcare conference is a testament to the
value, innovation, quality, and many unique attributes of our CARD
microfluidic devices," said Tony Eisenhut, Rheonix president. "We have created
a fully-automated, elegantly simple approach to molecular diagnostic testing
that we believe will benefit all aspects of the marketplace, including
patients, physicians, laboratories, and payors. We look forward to continuing
to share our story with clinicians, investors, and the other distinguished
guests at the Siemens conference."

Initial applications currently targeted by Rheonix include STIs (sexually
transmitted infections), HAIs (hospital-acquired infections), respiratory
infections, and GI (gastrointestinal) infections.

The conference will be held at the Quadras Conference Center in Menlo Park,

For more information on the conference, visit

About Rheonix
Rheonix Inc. is committed to improving standards of care by making molecular
diagnostics available to more people, in more places, more often. Rheonix,
through experienced leadership and creative vision, has developed the
EncompassMDx™ platform, a highly customizable technology with unmatched
versatility and affordability. The platform performs fully automated, complex
molecular assays in an easy-to-use and economical format on the Rheonix CARD®
cartridge. With both the Rheonix CARD and EncompassMDx family of products,
Rheonix is well-positioned to penetrate key molecular diagnostic market
sectors, from reference labs through point-of-care and everywhere in between.
For more information, visit www.rheonix.com.

SOURCE Rheonix, Inc.

Website: http://www.rheonix.com
Contact: Michael Mason, 212-691-8087, michaelm@allencaron.com
Press spacebar to pause and continue. Press esc to stop.